Noninvasive Detection and Differentiation of Axonal Injury/Loss, Demyelination, and Inflammation
Technical Report,30 Sep 2014,29 Sep 2015
Washington University St. Louis United States
Pagination or Media Count:
During year 3 of this funding support, we have applied the developed tools to demonstrate that DBSI is the future of diffusion MRI to more accurately detect underlying white matter tact pathologies noninvasively. We have focused our effort in completing specific aim 3, the dexamethasone treatment of optic neuritis of experimental autoimmune encephalomyelitis EAE mice. We repeated immunohistochemical staining of all optic nerves from previous in vivo DBSI measurements to improve the quantification. Through the improved staining and the use of objective quantification approach we were able to establish the correlation of in vivo DBSI pathological metrics with corresponding Immunohistochemical staining. The most significant finding is that we have validated that DBSI derived axonal volume may be used to quantify the extent of axonal loss of optic nerve. The assessment of irreversible axonal loss in optic nerve may be extended to the rest of CNS and could potentially quantify the rate of axonal loss providing a biomarker of irreversible progression of multiple sclerosis.